Indian stocks: Visit www.stage2stocks.com →

Aytu BioPharma, Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, Aytu BioPharma is in Stage 4, the downtrend phase, now in week 5 (since Sep 23, 2026). It closed at $1.98, 31.7% below its 52-week high and below its 200-day average, which is falling.

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. More about the company

$1.98
+1.02% today
$21.5M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is AYTU early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 19w
S4 40w
S2 15w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 2w → S1 2w → S4 1w → S1 4w → S2 9w → S3 5w → S2 19w → S3 6w → S4 40w → S1 6w → S2 13w → S3 11w → S2 15w → S3 3w → S2 4w → S3 4w → S4 9w → S1 5w → S4 4w current
Total tracked: 165 weeks across 19 stage runs.

AYTU among Drug Manufacturers - Specialty & Generic37th of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…37AYTUStage 4 · wk 542−13.2%
vs 52W High
-31.7%
$1.94 lo$2.90 hi
31.7% below 52W high, ongoing decline
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 5
1w13w26w
Week 5, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-15.4%
200 DMA: $2.34 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.72x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-13.2%
3M
-8.3%
6M
-21.4%
YTD
-28.5%
1Y
-16.1%
Scan Membership
Breakout Watch
Latest: 2024-02-12
4 appearances in last 60 days. First seen: 2019-05-20.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 5 · Vol 0.72x
2026-10-21S4
Wk 5 · Vol 0.19x
2026-10-20S4
Wk 4 · Vol 0.21x
2026-10-19S4
Wk 4 · Vol 0.39x
2026-10-16S4
Wk 4 · Vol 0.81x
2026-10-15S4
Wk 4 · Vol 0.79x
2026-10-14S4
Wk 4 · Vol 0.82x
2026-10-13S4
Wk 3 · Vol 0.66x
2026-10-12S4
Wk 3 · Vol 0.61x
2026-10-09S4
Wk 3 · Vol 0.27x
2026-10-08S4
Wk 3 · Vol 0.14x
2026-10-07S4
Wk 3 · Vol 0.14x
Moving averages & range
50 DMA
$2.15
200 DMA
$2.34
52W High
$2.90
52W Low
$1.94
5D Low
$1.96
Resistance levels (recent highs)
20d High
$2.28
60d High
$2.40
120d High
$2.57
250d High
$2.90
Next resistance
+15.2%
to 20d High
ROE
-52.6%
Profit margin -24.8%
Dividend Yield
0.00%
P/B 0.6

Aytu BioPharma: quick answers

What stage is Aytu BioPharma in?

As of Oct 22, 2026, Aytu BioPharma (AYTU) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 23, 2026 and is in week 5. What the four stages mean

Is Aytu BioPharma in an uptrend?

No. Aytu BioPharma is in a Stage 4 downtrend. It trades 15.4% below its 200-day average, which is falling.

How far is Aytu BioPharma from its 52-week high?

Aytu BioPharma closed at $1.98 on Oct 22, 2026, 31.7% below its 52-week high of $2.90. Its 52-week low is $1.94.

How has Aytu BioPharma performed over the past year?

As of Oct 22, 2026, Aytu BioPharma is down 16.1% over the past year and down 28.5% so far in 2026.

Which sector and industry is Aytu BioPharma in?

Aytu BioPharma is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.